Patents by Inventor Peter Röttgen

Peter Röttgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
    Patent number: 9605066
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: March 28, 2017
    Assignee: BIOTEST AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
  • Use of antibodies for detection of IL-10
    Patent number: 9540436
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: January 10, 2017
    Assignee: BIOTEST AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
  • Transfer device for transferring bulk material
    Patent number: 9334130
    Abstract: A transfer device is configured for transferring bulk material from a barge floating on a body of water into at least one receiving device. At least one lifting lock is provided by way of which the barge can be raised, while floating, to a tilting height above the surface of the body of water, and at least one tilting device is provided by way of which the barge can be tilted such that the bulk material is poured from the barge into the receiving device.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: May 10, 2016
    Assignee: Thyssenkrupp Resource Technologies GmbH
    Inventors: Helmut Weber, Peter Röttgen, Wei Ye
  • HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Publication number: 20150218270
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.
    Type: Application
    Filed: January 7, 2015
    Publication date: August 6, 2015
    Inventors: Frank OSTERROTH, Christoph UHEREK, Christoph BRUECHER, Peter RÖTTGEN, Benjamin DAELKEN, André ENGLING, Chantal ZUBER, Niklas CZELOTH
  • HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Publication number: 20150064179
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (1L-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: FRANK OSTERROTH, CHRISTOPH UHEREK, CHRISTOPH BRUECHER, PETER RÖTTGEN, BENJAMIN DAELKEN, ANDRÉ ENGLING, CHANTAL ZUBER, NIKLAS CZELOTH, ANDREA WARTENBERG-DEMAND, MARCUS GUTSCHER, JUDITH WESSELS-KRANZ
  • Humanized anti-IL 10 antibodies for the treatment of systemic lupus erythematosus (SLE)
    Patent number: 8956607
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the IL-10 receptor ?(IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL- 10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: February 17, 2015
    Assignee: Biotest AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
  • Humanized anti-IL-10 antibodies for the treatment of systemic lupus erythematosus (SLE)
    Patent number: 8852871
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: October 7, 2014
    Assignee: Biotest AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
  • HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Publication number: 20120321617
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (IL-10), wherein said antibody or fragment thereof: (i) binds to the same region of IL-10 as the 1L-10 receptor ? (IL-I10Ra) and is not capable of binding IL-10 when the IL-10 is bound to the IL-10 receptor; and (ii) binds to IL-10 in homodimeric form by binding a discontinuous epitope comprising residues of both monomers. Further provided are related products and methods involving the use of the antibody or fragment thereof.
    Type: Application
    Filed: November 30, 2010
    Publication date: December 20, 2012
    Applicant: BIOTEST AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth
  • HUMANIZED ANTI-IL 10 ANTIBODIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Publication number: 20120321618
    Abstract: Provided is a humanized or chimeric antibody or fragment thereof capable of binding to interleukin-10 (Th-10), wherein said antibody or fragment thereof is capable of being administered to a subject in the absence of an intolerable increase in the level of pro-inflammatory cytokines. Further provided are methods of treatment involving the use of the antibody or fragment thereof.
    Type: Application
    Filed: November 30, 2010
    Publication date: December 20, 2012
    Applicant: BIOTEST AG
    Inventors: Frank Osterroth, Christoph Uherek, Christoph Bruecher, Peter Röttgen, Benjamin Daelken, André Engling, Chantal Zuber, Niklas Czeloth, Andrea Wartenberg-Demand, Marcus Gutscher, Judith Wessels-Kranz
  • Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types
    Patent number: 7901677
    Abstract: Described is the use of a recombinant antibody comprising a binding site specific for an epitope of the laminin receptor or laminin receptor precursor for the treatment or diagnosis of various cancers, particularly B-CLL. Preferably, this antibody additionally comprises a binding site for at least one particular cell surface antigen.
    Type: Grant
    Filed: April 5, 2006
    Date of Patent: March 8, 2011
    Assignee: Affimed Therapeutics AG
    Inventors: Melvyn Little, Stefan Knackmuss, Uwe Reusch, Sergey Kipriyanov, Fabrice Le Gall, Vera Mick, Karin Hoffmann, Peter Röttgen
  • Single-chain antibody acting against 37 kDa/67 kDa Iaminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof
    Patent number: 7507797
    Abstract: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: March 24, 2009
    Assignee: Affimed Therapeutics AG
    Inventors: Stefan Knackmuss, Clémence Rey, Peter Röttgen, Claudia Büttner, Uwe Reusch
  • Single-chain antibody acting against 37 kda/67 kda laminin receptor as tools for the diagnosis and therapy of prion diseases and cancer, production and use thereof
    Publication number: 20070041977
    Abstract: Single-chain antibodies are described which specifically recognize both the 37 kDa precursor form of the laminin receptor (37 kDa LRP) and the 67 kDa high-affinity form of the laminin receptor (67 kDa LR), and pharmaceutical and diagnostic compositions which contain these single-chain antibodies.
    Type: Application
    Filed: October 8, 2004
    Publication date: February 22, 2007
    Inventors: Stefan Knackmuss, Clemence Rey, Peter Rottgen, Claudia Buttner, Uwe Reusch
  • Generation of diversity in combinatorial libraries
    Publication number: 20050085633
    Abstract: The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including enzyme inhibitors, agonists and antagonists for receptors, competitive binding peptides to a defined target, diagnostic ligands for diseases and autoimmune syndromes, including surveillance tools for immune status, post-translationally modified peptides, and such ligands generated by this technology.
    Type: Application
    Filed: August 13, 2003
    Publication date: April 21, 2005
    Applicant: COSMIX MOLECULAR BIOLOGICALS GMBH
    Inventors: John Collins, Peter Rottgen
  • Generation of diversity in combinatorial libraries
    Patent number: 6640192
    Abstract: The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including enzyme inhibitors, agonists and antagonists for receptors, competitive binding peptides to a defined target, diagnostic ligands for diseases and autoimmune syndromes, including surveillance tools for immune status, post-translationally modified peptides, and such ligands generated by this technology.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: October 28, 2003
    Assignee: Cosmix Molecular Biologicals GmbH
    Inventors: John Collins, Peter Röttgen
  • Generation of diversity in combinatorial libraries
    Publication number: 20020072594
    Abstract: The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including enzyme inhibitors, agonists and antagonists for receptors, competitive binding peptides to a defined target, diagnostic ligands for diseases and autoimmune syndromes, including surveillance tools for immune status, post-translationally modified peptides, and such ligands generated by this technology.
    Type: Application
    Filed: July 24, 2001
    Publication date: June 13, 2002
    Applicant: Cosmix Molecular Biologicals GmbH
    Inventors: John Collins, Peter Rottgen
  • Generation of diversity in combinatorial libraries
    Patent number: 6310191
    Abstract: The invention concerns gene banks and combinatorial derivatives thereof, prepared using phagemid- or phage-display in combination with type IIS restriction enzymes and cosmid packaging; their use for the isolation of ligands, including enzyme inhibitors, agonists and antagonists for receptors, competitive binding peptides to a defined target, diagnostic ligands for diseases and autoimmune syndromes, including surveillance tools for immune status, post-translationally modified peptides, and such ligands generated by this technology.
    Type: Grant
    Filed: July 30, 1999
    Date of Patent: October 30, 2001
    Assignee: Cosmix Molecular Biologicals GmbH
    Inventors: John Collins, Peter Röttgen